CN1622832A - 用于动脉粥样硬化和易病变性斑块成像的标记的巨噬细胞清除剂受体拮抗剂 - Google Patents

用于动脉粥样硬化和易病变性斑块成像的标记的巨噬细胞清除剂受体拮抗剂 Download PDF

Info

Publication number
CN1622832A
CN1622832A CNA028087704A CN02808770A CN1622832A CN 1622832 A CN1622832 A CN 1622832A CN A028087704 A CNA028087704 A CN A028087704A CN 02808770 A CN02808770 A CN 02808770A CN 1622832 A CN1622832 A CN 1622832A
Authority
CN
China
Prior art keywords
substituted
compound
independently selected
alkyl
direct bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028087704A
Other languages
English (en)
Chinese (zh)
Inventor
D·S·爱德华兹
S·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of CN1622832A publication Critical patent/CN1622832A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028087704A 2001-02-23 2002-02-22 用于动脉粥样硬化和易病变性斑块成像的标记的巨噬细胞清除剂受体拮抗剂 Pending CN1622832A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27095401P 2001-02-23 2001-02-23
US60/270,954 2001-02-23

Publications (1)

Publication Number Publication Date
CN1622832A true CN1622832A (zh) 2005-06-01

Family

ID=23033552

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028087704A Pending CN1622832A (zh) 2001-02-23 2002-02-22 用于动脉粥样硬化和易病变性斑块成像的标记的巨噬细胞清除剂受体拮抗剂

Country Status (12)

Country Link
US (2) US6869590B2 (enExample)
EP (1) EP1377321A4 (enExample)
JP (1) JP2004530654A (enExample)
CN (1) CN1622832A (enExample)
AU (1) AU2002254000A1 (enExample)
BR (1) BR0207521A (enExample)
CA (1) CA2438174A1 (enExample)
CZ (1) CZ20032564A3 (enExample)
HU (1) HUP0400027A3 (enExample)
IL (1) IL157444A0 (enExample)
MX (1) MXPA03007534A (enExample)
WO (1) WO2002067761A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116473020A (zh) * 2022-11-18 2023-07-25 新乡医学院 一种Macrosialin基因缺失动脉粥样硬化小鼠模型的构建方法及其应用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010035A (es) * 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
CA2449828A1 (en) * 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
CA2461836A1 (en) * 2001-10-16 2003-04-24 Epix Medical, Inc. Detection and treatment of intravascular lesions
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
AU2002337926B8 (en) * 2002-11-05 2008-02-28 Ion Beam Applications S.A. Stabilization of radiopharmaceuticals labeled with 18-F
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
GB0228490D0 (en) * 2002-12-06 2003-01-08 Amersham Plc Novel imaging compounds
US7297154B2 (en) 2003-02-24 2007-11-20 Maxwell Sensors Inc. Optical apparatus for detecting and treating vulnerable plaque
US7153299B1 (en) 2003-02-24 2006-12-26 Maxwell Sensors Inc. Optical apparatus for detecting and treating vulnerable plaque
US7803352B2 (en) * 2003-03-07 2010-09-28 John Steele Fisher Method for continuous visualization of a blood clot or plaque in body lumen
JP4680185B2 (ja) 2003-05-30 2011-05-11 パーデュー・リサーチ・ファウンデーション アテローム性動脈硬化症の診断法
CN1859904A (zh) * 2003-10-03 2006-11-08 默克公司 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂
EP1602931A1 (en) * 2004-06-03 2005-12-07 Universiteit Leiden SR-A antagonists
US20080206150A1 (en) * 2004-06-25 2008-08-28 The Regents Of The University Of California Nanoparticles for Imaging Atherosclerotic Plaque
US7575738B2 (en) 2004-08-13 2009-08-18 General Electric Company Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US7874975B2 (en) * 2005-07-20 2011-01-25 Clear Vascular, Inc. Methods and compositions for treating luminal inflammatory disease
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US20070196282A1 (en) * 2006-02-21 2007-08-23 Siemens Medical Solutions Usa, Inc. Medical diagnostic ultrasound with temperature-dependent contrast agents
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
EP2109466B1 (en) 2007-02-07 2014-11-12 Purdue Research Foundation Positron emission tomography imaging method
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
RU2474435C2 (ru) * 2007-11-07 2013-02-10 Джи-И Хелткер БВ Стабилизация радиофармацевтических композиций
US9717896B2 (en) 2007-12-18 2017-08-01 Gearbox, Llc Treatment indications informed by a priori implant information
US20090287120A1 (en) 2007-12-18 2009-11-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Circulatory monitoring systems and methods
US8636670B2 (en) 2008-05-13 2014-01-28 The Invention Science Fund I, Llc Circulatory monitoring systems and methods
US8361438B2 (en) * 2008-01-08 2013-01-29 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
EP2451776B1 (en) 2009-07-08 2019-09-18 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US20150023873A1 (en) 2011-11-11 2015-01-22 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
DE112016001921B4 (de) 2015-06-09 2025-03-20 Cummins Filtration Ip, Inc. Kurbelgehäuseentlüftungssysteme, die rotierende Tropfenabscheidervorrichtungen verwenden
WO2019034500A1 (en) * 2017-08-15 2019-02-21 Koninklijke Philips N.V. INTRALUMINAL ULTRASONIC DEVICE WITH ADJUSTABLE FREQUENCY
US10933146B2 (en) * 2017-12-12 2021-03-02 Massachusetts Institute Of Technology Cell-permeable imaging sensors and uses thereof
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577042A (en) * 1983-03-17 1986-03-18 California Institute Of Technology Homogeneous coordination compounds as oxidation catalysts
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4752141A (en) 1985-10-25 1988-06-21 Luxtron Corporation Fiberoptic sensing of temperature and/or other physical parameters
EP0247156B1 (en) 1985-11-18 1993-06-23 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
GB8603537D0 (en) 1986-02-13 1986-03-19 Parker D Conjugate compound
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
EP0416033B1 (en) 1988-05-25 1996-03-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Macrocyclic chelates and methods of use thereof
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
LU87403A1 (fr) 1988-12-06 1990-07-10 Oreal Procede de teinture de fibres keratiniques avec un hydroxyindole,associe a un derive quinonique
DE69024826T2 (de) 1989-02-10 1996-06-27 Celltech Therapeutics Ltd Aza-Macrozyklen und Verfahren zu deren Herstellung
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US4986671A (en) 1989-04-12 1991-01-22 Luxtron Corporation Three-parameter optical fiber sensor and system
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
AU7587091A (en) 1990-03-26 1991-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A fonctionalized complexand
US5275594A (en) 1990-11-09 1994-01-04 C. R. Bard, Inc. Angioplasty system having means for identification of atherosclerotic plaque
EP0565930A1 (en) 1992-03-27 1993-10-20 Nihon Medi-Physics Co., Ltd. Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
US5310535A (en) 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
AU2194695A (en) 1994-03-28 1995-10-17 Regents Of The University Of California, The Method for preparing radionuclide-labeled chelating agent-ligand complexes
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US5879659A (en) 1996-03-13 1999-03-09 Dupont Pharmaceuticals Company Ternary radiopharmaceutical complexes
US5848367A (en) 1996-09-13 1998-12-08 Sony Corporation System and method for sharing a non-volatile memory element as a boot device
US6403054B1 (en) 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
WO1999007382A1 (en) 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2000003704A1 (en) * 1998-07-20 2000-01-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
JP2002521437A (ja) 1998-07-30 2002-07-16 スミスクライン・ビーチャム・コーポレイション マクロファージ・スカベンジャー受容体アンタゴニスト

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116473020A (zh) * 2022-11-18 2023-07-25 新乡医学院 一种Macrosialin基因缺失动脉粥样硬化小鼠模型的构建方法及其应用

Also Published As

Publication number Publication date
BR0207521A (pt) 2004-06-01
IL157444A0 (en) 2004-03-28
AU2002254000A1 (en) 2002-09-12
JP2004530654A (ja) 2004-10-07
EP1377321A2 (en) 2004-01-07
US6974567B2 (en) 2005-12-13
US20040057900A1 (en) 2004-03-25
MXPA03007534A (es) 2003-12-04
CA2438174A1 (en) 2002-09-06
US20020127181A1 (en) 2002-09-12
HUP0400027A2 (hu) 2004-04-28
US6869590B2 (en) 2005-03-22
CZ20032564A3 (cs) 2004-09-15
WO2002067761A2 (en) 2002-09-06
EP1377321A4 (en) 2006-01-11
WO2002067761A3 (en) 2003-02-13
HUP0400027A3 (en) 2006-01-30

Similar Documents

Publication Publication Date Title
CN1622832A (zh) 用于动脉粥样硬化和易病变性斑块成像的标记的巨噬细胞清除剂受体拮抗剂
Schottelius et al. Ligands for mapping αvβ3-integrin expression in vivo
JP5676673B2 (ja) 癌の画像化および処置
CN1078480C (zh) 生长激素抑制素结合肽－金属络合物
CN1154072A (zh) 用于成象的锝-99m标记的肽
RS61394B1 (sr) 18f-obeleženi inhibitori specifičnog membranskog antigena prostate (psma) i njihova upotreba kao sredstava za vizuelizaciju kancera prostate
CN113710286A (zh) 具有改善的组织特异性的前列腺特异性膜抗原(psma)配体
Zhao et al. Synthesis and evaluation of 68Ga-and 177Lu-labeled (R)-vs (S)-DOTAGA prostate-specific membrane antigen-targeting derivatives
CN1298390C (zh) 心脏灌注和玻连蛋白受体靶向成像剂的同时成像
KR20250073273A (ko) 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
CN1582166A (zh) 在联合疗法中应用的玻璃粘连蛋白受体拮抗药物
JPH06507174A (ja) ニューロキニン１レセプターを有する組織を検出および局部化する方法
JP2007512321A (ja) 造影剤
Prinsen et al. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis
JP5709522B2 (ja) 新規イメージング法
CN101039702A (zh) 作为靶向试剂用于内皮－特异性体内转导的热激蛋白
CN1901941A (zh) 血管紧张素ii与成像部分的缀合物
CN1874792A (zh) 包含基质金属蛋白酶底物的化合物及其使用方法
EP4640240A1 (en) Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
TW202502800A (zh) 一種成纖維細胞活化蛋白配體及其用途
WO2024153719A1 (en) Dual labelled compounds targeting the prostate specific membrane antigen
Azad Development of Single and Multimodality Imaging Probes for PET, SPECT and Fluorescence Imaging
Behnam Azad Development of Single and Multimodality Imaging Probes for PET, SPECT and Fluorescence Imaging
Bugaj Octreotate: A new somatostatin analogue for tumor imaging and radionuclide therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication